Robert Cardwell (@RFCardwell) header
Robert Cardwell (@RFCardwell) profile picture

I tweet about sharks, human genetics, and bioscience in general. Chief Strategy Officer at @GeneticsAmerica, Board Member at PanGIA Biotech. Bluenose.

Biscayne Bay, Florida
Joined July 2015
Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)Photo by Robert Cardwell (@RFCardwell)
Happy Veterans Day.
11
Happy 251st Marine Corps birthday. cmc.marines.mil/Birthday/
1
57
Robert Cardwell retweeted
Modern diagnostics can generate enormous amounts of biological information. The challenge is interpreting what matters within that complexity. This is one reason machine learning approaches are being explored in oncology diagnostics. Not to replace clinical judgment, but to assist in evaluating multidimensional biomolecular patterns that may not be obvious in isolation. PanGIA Biotech’s AACR 2026 research evaluated machine learning-assisted analysis of biochemical signatures derived from urine samples using proprietary hydrogel microarrays. Because generating more data and generating more useful insight are not always the same thing. #Oncology #AIinHealthcare #Diagnostics #ClinicalResearch
1
32
I'll be speaking about these AACR presentations this afternoon at Executive War College in New Orleans.
As the conversation around early cancer detection continues to evolve, one question remains: How do we move toward non-invasive approaches that clinicians can realistically integrate into care? At the @AACR Annual Meeting 2026, PanGIA Biotech will present two accepted abstracts exploring: • Oral sample-based detection for oral cancer • Urine-based analysis for multi-cancer detection These studies reflect continued development of the PanGIA Analysis System (PAS), a machine learning platform designed to analyze complex biomolecular signals from non-invasive samples. We look forward to contributing to the broader clinical and research conversation shaping the future of cancer diagnostics. Link to press release available in the comments.
62
Happy Lab Week 2026 to the Team at Genetics Institute of America! Each of you do so much fantastic work every day, I'm honored to work with each of you. @GeneticsAmerica
25
PanGIA Biotech CEO and Chief Scientific Officer will be at AACR 2026 in San Diego.
As the conversation around early cancer detection continues to evolve, one question remains: How do we move toward non-invasive approaches that clinicians can realistically integrate into care? At the @AACR Annual Meeting 2026, PanGIA Biotech will present two accepted abstracts exploring: • Oral sample-based detection for oral cancer • Urine-based analysis for multi-cancer detection These studies reflect continued development of the PanGIA Analysis System (PAS), a machine learning platform designed to analyze complex biomolecular signals from non-invasive samples. We look forward to contributing to the broader clinical and research conversation shaping the future of cancer diagnostics. Link to press release available in the comments.
58
Enjoying insights at Business of Biotech Conference at Moffitt Cancer Center.
2
37
"While alone, Michael Collins orbited the moon 14 times..." airandspace.si.edu/amp-stori…
20
Happy to share our latest publication.
Diagnostics published a peer-reviewed study evaluating a urine-based, machine learning–driven liquid biopsy for prostate cancer detection. The study, based on PanGIA Biotech’s GH-215 clinical program, demonstrated 97.8% sensitivity across disease grades. With this publication, these findings enter the clinical literature, advancing a pattern-based approach to cancer detection using biomolecular signatures. PanGIA Biotech’s platform moves beyond single-marker signals toward a more comprehensive view of disease, with a focus on detecting cancer earlier and without invasive procedures. Because when detection can happen earlier, and without invasive procedures, it changes how quickly patients and families can move from uncertainty to informed decisions. Read the full press release: bit.ly/3QfB1eJ #LiquidBiopsy #ProstateCancer #Oncology #Diagnostics #PrecisionMedicine
21